H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on RMTI stock, giving a Buy rating on August 16.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ram Selvaraju has given his Buy rating due to a combination of factors that highlight Rockwell Medical’s potential for growth and stability. The company’s recent financial results were in line with expectations, and it has reiterated its revenue guidance for 2025, indicating confidence in its financial outlook. Despite 2025 being considered a trough year, Rockwell Medical is expected to diversify and expand its revenue streams and customer base significantly.
Key to this optimistic outlook are the long-term contracts Rockwell Medical has secured with major dialysis service providers, which enhance revenue predictability and stability. These agreements, including those with Innovative Renal Care and other significant health systems, position the company as a leading supplier in the dialysis market. Additionally, Rockwell Medical is actively expanding its presence in the western U.S. and exploring new product opportunities, which could further bolster its market position and financial performance.
Selvaraju covers the Healthcare sector, focusing on stocks such as Cognition Therapeutics, Axsome Therapeutics, and Urogen Pharma. According to TipRanks, Selvaraju has an average return of 23.1% and a 54.71% success rate on recommended stocks.
In another report released on August 16, Maxim Group also maintained a Buy rating on the stock with a $5.00 price target.